Jimmy Mascaro, DO
Psychiatry · Ottumwa, IANPI 1104998251
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $314,795 of the $360,784 with a category attached, or 87.3%. AbbVie accounts for 70.1% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $105,768, 4.0 times the $26,654 reported in 2019. Among psychiatry clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 609 payments — averaging $592.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$253K
- Vanda Pharmaceuticals Inc.$104K
- E.r. Squibb & Sons, L.L.C.$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Lundbeck LLC$466
- Alkermes, Inc.$162
- plus $387 from 9 others
What the payments were for
- Consulting fees$1,8401%
- Speaking & faculty fees$314,79587%
- Travel & lodging$34,39210%
- Food & beverage$9,7063%
- Education$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 370 | $252,942 |
| Vanda Pharmaceuticals Inc. | 150 | $103,530 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,840 |
| Otsuka America Pharmaceutical, Inc. | 39 | $1,456 |
| Lundbeck LLC | 17 | $466 |
| Alkermes, Inc. | 8 | $162 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $76 |
| Johnson & Johnson | 5 | $72 |
| Sunovion Pharmaceuticals Inc. | 5 | $71 |
| Neurocrine Biosciences, Inc. | 4 | $58 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Corium, LLC | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$247,237
- Fanapt$102,014
- REXULTI$483
- ABILIFY ASIMTUFII$482
- ABILIFY MAINTENA$482
- ARISTADA$450
- ARISTADA INITIO$112
How this compares
$360,784 in reported general payments places this provider in the 95th percentile of 245 psychiatry providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 427 | $614,264 |
| Invega SustennaPaliperidone Palmitate | 55 | $202,462 |
| AustedoDeutetrabenazine | 25 | $122,444 |
| Abilify AsimtufiiAripiprazole | 15 | $75,282 |
| Risperdal ConstaRisperidone Microspheres | 38 | $54,270 |
| Lurasidone Hcl | 53 | $13,468 |
| TrintellixVortioxetine Hydrobromide | 22 | $10,509 |
| Aripiprazole | 121 | $7,490 |
| Quetiapine Fumarate | 545 | $6,451 |
| FetzimaLevomilnacipran Hcl | 12 | $5,844 |
| Fluphenazine Hcl | 39 | $4,243 |
| Atomoxetine Hcl | 27 | $3,902 |
| Buspirone Hcl | 208 | $3,406 |
| Duloxetine Hcl | 219 | $3,363 |
| Vilazodone Hcl | 31 | $3,208 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima | $252,942 | $620,108439 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $72 | $256,73293 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $31 | $122,44425 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii | $1,456 | $75,28215 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $30 | $10,50922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 245 psychiatry providers in Iowa.
Other psychiatry in Ottumwa
- Charles JennischUrbandale$949K
- Manmohan SinghDes Moines$408K
- Alan WhittersCedar Rapids$170K
- Donald BlackIowa City$19K
- William CoryellIowa City$18K
- Randall KavalierWest Des Moines$15K
- Dwight SchroederCedar Rapids$13K
- Rodney DeanSioux City$11K
- Peggy NopoulosIowa City$11K
- Darko ZdilarWaterloo$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.